Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 09 Feb 2023
EMA confirms acceptance of application for AVT04, a proposed biosimilar to Stelara (ustekinumab)
9 February 2023 - EMA opinion on AVT04 could come as soon as the second half of 2023. ...
Posted by Michael Wonder on 09 Feb 2023
Nexus Pharmaceuticals receives FDA approval for tirofiban hydrochloride injection
9 February 2023 - Nexus Pharmaceuticals announced that it has received US FDA approval for tirofiban hydrochloride injection in 5 ...
Posted by Michael Wonder on 09 Feb 2023
Digital mental health tech for children and young people recommended by NICE in first rapid healthtech guidance
8 February 2023 - Four digital technologies that can help children and young people with mild to moderate symptoms of anxiety ...
Posted by Michael Wonder on 09 Feb 2023
COVID-19 vaccine safety report (09 February 2023)
9 February 2023 - To 5 February 2023, over 44 million doses of Comirnaty have been administered in Australia, as well ...
Posted by Michael Wonder on 09 Feb 2023
Biden’s SOTU targets drug companies, but misses opportunity to challenge health insurers and pharmacy benefit managers
8 February 2023 - President Biden’s State of the Union Address hammered home the point that drug prices must come down. ...
Posted by Michael Wonder on 09 Feb 2023
Biden to push for insulin cost caps, but unlikely to secure Congressional approval
8 February 2023 - US President Joe Biden will call for a nationwide cap of $35 a month on out ...
Posted by Michael Wonder on 09 Feb 2023
Lorlatinib for the first-line treatment of patients with ALK positive advanced non-small-cell lung cancer
9 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 Feb 2023
Dapagliflozin propanediol monohydrate for the treatment of patients with chronic heart failure with preserved or mildly reduced ejection fraction
8 February 2023 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 09 Feb 2023
Empagliflozin for the treatment of patients with chronic heart failure with preserved or mildly reduced ejection fraction
8 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 Feb 2023
NICE recommends genetic test to prevent newborn babies going deaf
9 February 2023 - A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a ...
Posted by Michael Wonder on 09 Feb 2023
Availability of Sanofi’s Nexviadyme (avalglucosidase alfa) provides NHS with new treatment for Pompe disease
8 February 2023 - Sanofi announced today that health care specialists and patients living with Pompe disease will now have ...
Posted by Michael Wonder on 09 Feb 2023
FDA grants regenerative medicine advanced therapy designation for rexlemestrocel-L in chronic low back oain
9 February 2023 - Mesoblast today announced that the US FDA's Office of Tissues and Advanced Therapies has granted regenerative ...
Posted by Michael Wonder on 09 Feb 2023
Quebec becomes first province to cover Brukinsa (zanubrutinib) for the treatment of Waldenström's macroglobulinemia
6 February 2023 - First and only Bruton's tyrosine kinase inhibitor to be granted provincial formulary approval. ...
Posted by Michael Wonder on 09 Feb 2023
CoolHealth enters US market with TargetCool, a breakthrough FDA class II medical device offering unprecedented precise, rapid cooling for pain management and bruise minimisation
8 February 2023 - CoolHealth is entering the US market with a breakthrough FDA Class II medical device, TargetCool. ...
Posted by Michael Wonder on 09 Feb 2023
Eylea (aflibercept) injection approved as the first pharmacological treatment for preterm infants with retinopathy of prematurity by the FDA
8 February 2023 - Eylea now approved to treat five retinal conditions caused by ocular angiogenesis. ...